- Mots-clés > cannabis, cannabidiol
- Mots-clés > controlled medications
- Mots-clés > Expert Committee on Drug Dependence (ECDD)
- Mots-clés > international drug control system
- Mots-clés > narcotic drugs
- Mots-clés > narcotics control
- Mots-clés > psychoactive substances
- Mots-clés > psychotropic substance
- Mots-clés > substance evaluation - process
(2018; 60 pages)
This report presents the recommendations of the fortieth WHO Expert Committee on Drug Dependence (ECDD). The ECDD is responsible for the assessment of psychoactive substances for possible scheduling under the International Drug Control Conventions. The ECDD reviews the therapeutic usefulness, the liability for abuse and dependence, and the public health and social harm of each substance. The ECDD will advise the Director-General of WHO, to schedule or to amend the scheduling status of a substance. The Director-General will, as appropriate, communicate the recommendations to the Secretary-General of the United Nations, who will in turn communicate the advice to the Commission on Narcotic Drugs (CND).
The report summarizes the findings of the fortieth meeting, which was dedicated to the review of cannabis and its component substances. This included a critical review of cannabidiol and pre-reviews of cannabis plant and resin; extracts and tinctures of cannabis; Δ9 - tetrahydrocannabinol ((Δ9 -THC)); and isomers of THC. The Committee recommended that preparations considered to be pure cannabidiol should not be scheduled within the International Drug Control Conventions. The Committee concluded that there is sufficient evidence to proceed to a critical review of cannabis plant and resin; extracts and tinctures of cannabis; Δ9 -THC and isomers of Δ9 -THC.